Biofrontera (BFRI) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biofrontera (BFRI) has outperformed Pasithea Therapeutics (KTTA) over the past year, losing 9.0% versus a loss of 46.2%. Pasithea Therapeutics is the larger company by market cap ($14.7 million vs $13.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | KTTA |
|---|---|---|
| Share price | $0.9188 | $0.4409 |
| Market cap | $13.65M | $14.73M |
| 1-day change | -1.77% | -0.56% |
| YTD return | +61.19% | -65.82% |
| 1-year return | -9.03% | -46.23% |
| 5-year return | — | -99.26% |
| Forward P/E | 2.14 | — |
| EPS (TTM) | $-0.43 | $-1.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.66 | $2.06 |
| 52-week low | $0.555 | $0.281 |
| Distance from 52-week high | -44.65% | -78.60% |
| Analyst consensus | none | none |
| Avg. price target upside | +553.03% | +580.43% |
| Average volume | 547.45K | 225.69K |
| Shares outstanding | 14.85M | 33.41M |
| Employees | 84 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed KTTA by 37.2 percentage points over the past year.
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Healthcare · Drug Manufacturers - Specialty & Generic · 84 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Healthcare · Biotechnology · 5 employees
BFRI vs KTTA FAQ
Which is bigger, Biofrontera or Pasithea Therapeutics?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $14.73M compared with $13.65M for Biofrontera (BFRI).
Which stock has performed better over the past year, BFRI or KTTA?
BFRI returned -9.03% over the past 12 months, compared with -46.23% for KTTA (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and Pasithea Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Biofrontera and Biotechnology for Pasithea Therapeutics.